Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16698319 | 0.89 | HTR6 (0.49) | HTR6AKR1C3AKR1C1HTR2ACA12 | |
| SCHEMBL29377395 | 0.86 | HTR6 (0.52) | HTR6CA1CA2LMNACYP3A4 | |
| SCHEMBL12449919 | 0.86 | HTR6 (0.52) | HTR6CA1CA2LMNACYP3A4 | |
| SCHEMBL29651100 | 0.85 | HTR6 (0.64) | HTR6AKR1C3AKR1C1HTR2AHTR7 | |
| SCHEMBL1996382 | 0.85 | HTR6 (0.64) | HTR6AKR1C3AKR1C1HTR2AHTR7 | |
| SCHEMBL4334765 | 0.83 | HTR6 (0.52) | HTR6AKR1C3AKR1C1CA12CA1 | |
| SCHEMBL19737423 | 0.83 | HTR6 (0.59) | HTR6AKR1C3AKR1C1HTR7CA12 | |
| SCHEMBL12954860 | 0.83 | HTR6 (0.58) | HTR6HTR2AHTR7LMNASMN1; SMN2 | |
| SCHEMBL19737553 | 0.81 | HTR6 (0.49) | HTR6AKR1C3AKR1C1HTR7CA12 | |
| SCHEMBL1468385 | 0.81 | AKR1C3 (0.60) | HTR6AKR1C3AKR1C1HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2548863-A1 | New CRTh2 antagonists. | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| CN-101573332-A | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | CN | disclosed |
| EP-2081890-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055847-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167361-A1 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | HTR6, HTR1B, HTR1F | HTR6 1/4885AKR1C3 2617/4885AKR1C1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.